Dyne Therapeutics (NASDAQ:DYN) Trading Down 4.2% – Time to Sell?

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s share price dropped 4.2% during trading on Friday . The company traded as low as $29.73 and last traded at $29.82. Approximately 176,628 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 1,474,617 shares. The stock had previously closed at $31.13.

Analyst Upgrades and Downgrades

DYN has been the subject of a number of recent research reports. Chardan Capital reiterated a “buy” rating and issued a $50.00 target price on shares of Dyne Therapeutics in a report on Wednesday, November 13th. Morgan Stanley boosted their target price on shares of Dyne Therapeutics from $48.00 to $52.00 and gave the stock an “overweight” rating in a report on Wednesday, August 14th. Piper Sandler reiterated an “overweight” rating and issued a $53.00 target price on shares of Dyne Therapeutics in a report on Monday, September 23rd. JPMorgan Chase & Co. lowered Dyne Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $43.00 to $35.00 in a research note on Thursday, October 24th. Finally, Stifel Nicolaus boosted their price target on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $50.82.

Dyne Therapeutics Stock Down 1.7 %

The stock has a 50-day moving average of $31.78 and a 200 day moving average of $35.36. The stock has a market cap of $3.12 billion, a PE ratio of -8.74 and a beta of 1.10.

Dyne Therapeutics (NASDAQ:DYN) last issued its earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). On average, equities analysts anticipate that Dyne Therapeutics, Inc. will post -3.45 EPS for the current year.

Insiders Place Their Bets

In other Dyne Therapeutics news, Director Dirk Kersten sold 79,411 shares of the company’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $36.45, for a total value of $2,894,530.95. Following the sale, the director now owns 234,127 shares in the company, valued at approximately $8,533,929.15. This represents a 25.33 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Carlo Incerti sold 16,500 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $28.73, for a total value of $474,045.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 176,257 shares of company stock worth $6,193,718. Corporate insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Nisa Investment Advisors LLC raised its stake in shares of Dyne Therapeutics by 904.1% during the 2nd quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock worth $26,000 after buying an additional 669 shares during the period. Quantbot Technologies LP acquired a new position in shares of Dyne Therapeutics during the 3rd quarter worth approximately $34,000. Point72 DIFC Ltd acquired a new position in Dyne Therapeutics in the 3rd quarter valued at $36,000. US Bancorp DE lifted its holdings in Dyne Therapeutics by 776.9% in the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock valued at $49,000 after purchasing an additional 1,212 shares in the last quarter. Finally, Values First Advisors Inc. purchased a new position in Dyne Therapeutics in the 3rd quarter valued at $62,000. 96.68% of the stock is owned by institutional investors and hedge funds.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.